{"id":15388,"date":"2020-11-05T12:04:03","date_gmt":"2020-11-05T11:04:03","guid":{"rendered":"https:\/\/idibell.cat\/?p=15388"},"modified":"2020-11-05T12:04:03","modified_gmt":"2020-11-05T11:04:03","slug":"identificat-un-biomarcador-que-preveu-lincrement-de-malignitat-que-pot-causar-la-terapia-antiangiogenica-en-els-cancer-renals","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2020\/11\/identificat-un-biomarcador-que-preveu-lincrement-de-malignitat-que-pot-causar-la-terapia-antiangiogenica-en-els-cancer-renals\/","title":{"rendered":"Identificat un biomarcador que preveu l\u2019increment de malignitat que pot causar la ter\u00e0pia antiangiogenica en els c\u00e0ncer renals"},"content":{"rendered":"<p>L&#8217;angiog\u00e8nesi \u00e9s el proc\u00e9s pel qual els tumors creen nous vasos sanguinis que els hi aportaran els nutrients necessaris per seguir creixent. Els <strong>f\u00e0rmacs antiangiog\u00e8nics<\/strong> van dirigits precisament a bloquejar aquest proc\u00e9s. Aquest tipus de ter\u00e0pia dirigida sol tenir bons resultats a curt termini, disminuint el creixement tumoral, no obstant, diversos estudis apunten que aquests tractaments incrementen la capacitat d&#8217;invasi\u00f3 dels tumors i promouen un comportament m\u00e9s agressiu, empitjorant el pron\u00f2stic dels pacients. Estudis amb models animals han intentat desxifrar els mecanismes moleculars implicats en aquesta discrep\u00e0ncia, per\u00f2 hi ha molts interrogants que segueixen oberts.<\/p>\n<p>L&#8217;equip del <strong>Dr. Oriol Casanovas<\/strong> de l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (<a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/angiogenesi-tumoral\/\">IDIBELL<\/a>) i l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (<a href=\"http:\/\/ico.gencat.cat\/ca\/inici\">ICO<\/a>) ha investigat les conseq\u00fc\u00e8ncies del tractament antiangiog\u00e8nic en la capacitat d&#8217;invasi\u00f3 i met\u00e0stasi del c\u00e0ncer de rony\u00f3 amb l&#8217;objectiu d&#8217;identificar biomarcadors que determinin l&#8217;agressivitat d&#8217;aquests tumors.<\/p>\n<p>En l&#8217;estudi publicat avui a la revista <a href=\"https:\/\/www.embopress.org\/doi\/10.15252\/emmm.201911889\"><em>EMBO Molecular Medicine<\/em><\/a>, l&#8217;equip de Casanovas en col\u00b7laboraci\u00f3 amb cl\u00ednics de l\u2019Hospital de Bellvitge, de l\u2019Hospital de la Vall d\u2019Hebron i del VHIO demostra que els f\u00e0rmacs antiangiog\u00e8nics, en alguns casos, augmenten l&#8217;<strong>agressivitat<\/strong> dels tumors mentre que en altres aquesta no es veu afectada. &#8220;<em>Aquests resultats confirmen els efectes heterogenis dels tractaments antiangiog\u00e8nics, i com aquests poden afectar profundament la progressi\u00f3 natural dels tumors i induir malignitat<\/em>&#8220;, explica el <strong>Dr. Casanovas<\/strong>.<\/p>\n<p>Un cop confirmada l&#8217;heterogene\u00eftat de resposta calia identificar els senyals moleculars que la determinen, i que per tant, que permetrien escollir els pacients que resultarien beneficiats amb el tractament. L&#8217;estudi ha utilitzat diverses eines bioinform\u00e0tiques d&#8217;an\u00e0lisis gen\u00e8tiques i moleculars que han posat en evid\u00e8ncia la implicaci\u00f3 d\u2019una via de senyalitzaci\u00f3 cel\u00b7lular, concretament del gen ALDH1A3, en la resposta divergent enfront de la ter\u00e0pia antiangiog\u00e8nica.<\/p>\n<p>El <strong>Dr. Oriol Casanovas<\/strong> apunta que &#8220;<em>en aquest estudi hem identificat un <strong>nou biomarcador<\/strong> capa\u00e7 de predir si un pacient pot beneficiar-se m\u00e9s del tractament amb antiangiog\u00e8nics<\/em>&#8220;, i afegeix, &#8220;<em>aquestes troballes poden obrir la porta a noves dianes i estrat\u00e8gies terap\u00e8utiques dirigides a suprimir la malignitat d&#8217;aquests tractaments<\/em>&#8220;.<\/p>\n<p>&nbsp;<\/p>\n<h3>\u00a0Les eines de l\u2019estudi<\/h3>\n<p>&nbsp;<\/p>\n<p>Per tal d&#8217;estudiar el comportament dels tumors enfront del tractament amb antiangiog\u00e8nics, i determinar la variaci\u00f3 interpacient existent, els investigadors varen crear una bateria de <strong>models ortotr\u00f2pics de ratol\u00ed<\/strong>. Aquests models consisteixen en la implantaci\u00f3 de bi\u00f2psies de tumors renals de pacients en el mateix teixit de ratol\u00ed, la qual cosa permet reproduir la variabilitat entre pacients i identificar els aspectes clau de l&#8217;evoluci\u00f3 tumoral. Es tracta d&#8217;una eina precl\u00ednica amb molt potencial.<\/p>\n<p>L&#8217;estudi dels gens expressats pel tumors renals despr\u00e9s del tractament amb antiangiog\u00e8nics, i la seva correlaci\u00f3 amb la resposta tumoral posterior, ha perm\u00e8s identificar el biomarcador que pot discriminar entre tumors invasius i no-invasius<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudi del IDIBELL-ICO ha identificat no nom\u00e9s que la quimioter\u00e0pia antiangiog\u00e8nica pot induir m\u00e9s agressivitat i malignitat en els tumors renals, sin\u00f3 que tamb\u00e9, han identificat un biomarcador per preveure en quins pacients aix\u00f2 pot passar. Aquest descobriments s\u00f3n un pas m\u00e9s per a fer una ter\u00e0pia contra el c\u00e0ncer cada dia m\u00e9s personalitzada.<\/p>\n","protected":false},"author":8,"featured_media":15389,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[397,332,447,452],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 22:56:19","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/15388"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=15388"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/15388\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/15389"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=15388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=15388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=15388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}